Since the initial description of GLUT1-DS in 1991 (3), the only known medical therapy for GLUT1-DS is the classic ketogenic diet (cKD), a normocaloric, hyperlipidic, normoprotein and low-carbohydrate diet, whose main purpose is to induce the constant production of ketone bodies, mainly acetoacetate (ACA) and β-hydroxybutyrate (BHB). The gene discussed is SLC2A1; the disease is chronic kidney disease.